Onco Wiki / Bandera roja

Carcinoma endometrial candidato 2L con función adecuada del órgano y comorb...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDRF-ENDOMETRIAL-FIT-FOR-LENVATINIB-COMBO
TipoSeñal de alerta
Situaciónreviewed 2026-04-30 | pending_clinical_signoff
EnfermedadesDIS-ENDOMETRIAL
FuentesSRC-ESMO-ENDOMETRIAL-2022 SRC-NCCN-UTERINE-2025

Origen de la bandera roja

DefiniciónEndometrial carcinoma 2L candidate with adequate organ function and controllable comorbidities to tolerate pembrolizumab + lenvatinib combination per KEYNOTE-775 (Makker NEJM 2022). Captures the prereq bundle: BP controllable on antihypertensives, no recent major surgery (<3 weeks), no active GI bleeding, no severe cardiac dysfunction (LVEF >=45%), and no uncontrolled proteinuria (UP/C <1.0 g/g) — these are the dose-modifying triggers for lenvatinib that, if uncontrolled at baseline, gate combination eligibility per FDA label.
Dirección clínicaintensificar
Categoríaidoneidad para la aptitud
Algoritmo de cambiosALGO-ENDOMETRIAL-2L

Lógica de activación

{
  "all_of": [
    {
      "any_of": [
        {
          "finding": "uncontrolled_hypertension",
          "value": false
        },
        {
          "comparator": "<",
          "finding": "blood_pressure_systolic_mmhg",
          "threshold": 150
        }
      ]
    },
    {
      "any_of": [
        {
          "finding": "recent_surgery_within_3_weeks",
          "value": false
        },
        {
          "comparator": ">=",
          "finding": "weeks_since_last_surgery",
          "threshold": 3
        }
      ]
    },
    {
      "any_of": [
        {
          "finding": "active_gi_bleed",
          "value": false
        },
        {
          "finding": "gi_bleed_history_recent",
          "value": false
        }
      ]
    },
    {
      "any_of": [
        {
          "comparator": ">=",
          "finding": "lvef_percent",
          "threshold": 45
        },
        {
          "finding": "severe_cardiac_dysfunction",
          "value": false
        }
      ]
    },
    {
      "any_of": [
        {
          "finding": "proteinuria_uncontrolled",
          "value": false
        },
        {
          "comparator": "<",
          "finding": "up_c_ratio_g_per_g",
          "threshold": 1.0
        }
      ]
    }
  ],
  "type": "composite_score"
}

Notas

Aggregates the "Adequate organ function" + "lenvatinib toxicity tolerance required" gates from ALGO-ENDOMETRIAL-2L step 2. Each trigger axis defaults to "false" (i.e., NOT contraindicated) when finding absent — so patients without explicit contraindication documentation pass the gate. This is permissive-by-default which matches clinical practice (assume eligible unless documented ineligible). MDT brief should still surface lenvatinib-specific prerequisites for verbal confirmation. Patients flagged ineligible fall back to single-agent options (doxorubicin, paclitaxel re-challenge) outside current KB scope.

Utilizado por

Algoritmos